These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1005904)

  • 1. Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
    Cotzias GC; Papavasiliou PS; Ginos JZ
    Res Publ Assoc Res Nerv Ment Dis; 1976; 55():305-15. PubMed ID: 1005904
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease: new treatments.
    Stewart RM
    Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
    Dzudza M; Dzudza D
    Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment with L-dopa and amantadine in Parkinson's disease.
    Pendefunda G; Pollingher B; Stefanache F; Gavril A; Oprisan C; Merling M; Nemteanu E; Ciunru M; Koropitzer I
    Ther Hung; 1975; 23(1):12-6. PubMed ID: 1105871
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Parkinson's syndrome].
    Fortschr Med; 1982 Jun; 100(24):1172. PubMed ID: 7106681
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 10. Apomorphine increases blood glucose concentrations in Parkinson's disease.
    Tison F; Fouillet N; Henry P
    Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aporphines in Parkinson's disease.
    Cotzias GC; Papavasiliou PS; Tolosa E; Bell-Midura MA; Ginos JZ
    Trans Am Neurol Assoc; 1975; 100():178-81. PubMed ID: 1226602
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
    Gründig E; Gerstenbrand F
    Wien Klin Wochenschr; 1980 Dec; 92(24):868-71. PubMed ID: 7222702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapy of Parkinson's disease.
    Ajax T; Rodnitzky R; Dobson J
    Iowa Med; 1997 Jan; 87(1):27-9. PubMed ID: 9029838
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 19. Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
    Mastrosimone F; Colucci d'Amato C; De Angelis G; Iaccarino C; Giordano L; Marmo E
    J Med; 1980; 11(5-6):377-83. PubMed ID: 6962824
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: Alternatives to levodopa.
    Br Med J; 1976 May; 1(6019):1169-70. PubMed ID: 1268610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.